DALLAS, TX -- April 6th, 2025 -- Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate’s 4Q25 update continues to position CTx-1301 toward a potential commercial ADHD launch, with the regulatory focus now centered on manufacturing (CMC) rather than clinical performance. The NDA remains under FDA review under the 505(b)(2) pathway, and recent financing, IP progress, and commercial buildout efforts remain supportive of the broader investment thesis. Importantly, following the $12M PIPE completed in February 2026, the Company has a pro forma cash balance of approximately ~$23M, which we estimate provides runway into late 2026. Combined with ongoing access to capital through its ATM and ELOC facilities, we believe Cingulate is positioned to fund ongoing regulatory and manufacturing activities as it works toward resolution of remaining CMC items.
NDA Submission and FDA Approval Pathway: CTx-1301 remains under active FDA review, with recent feedback primarily related to chemistry, manufacturing, and controls (CMC). Importantly, the Company has not received any material safety or efficacy questions, and regulatory engagement to date has been focused on ensuring consistency and validation of the manufacturing process for CTx-1301’s differentiated multi-release formulation. Following a February 2026 pre-approval inspection of the Company’s contract manufacturing partner, the FDA issued a Form 483 with three observations, which management has indicated are being addressed. In our view, these items appear consistent with typical manufacturing validation for a novel delivery system and are addressable in nature, rather than indicative of a fundamental issue with the product. As a result, the regulatory timeline may shift modestly beyond the May 31, 2026 PDUFA date, with the key gating factor now centered on completing additional process validation work and providing supporting data to the FDA. We view this as a timing and execution dynamic, not a thesischanging event, and continue to believe the program remains on track for approval following resolution of these items.
Clinical Context: CTx-1301 is being reviewed under the FDA’s 505(b)(2) pathway, which allows the Company to leverage existing clinical data for the active ingredient (dexmethylphenidate). As such, the regulatory focus is primarily on pharmacokinetics, delivery profile, and manufacturing consistency, rather than requiring a fully de novo demonstration of efficacy. While the adult Phase 3 study did not achieve statistical significance on its primary endpoint, we do not view this as a critical factor in the approval process given the 505(b)(2) framework and the demonstrated pharmacokinetic equivalence to existing approved therapies. Supporting data, including secondary endpoints and overall effect size, continue to reinforce the product’s differentiated profile.
Investment View: We believe the key near-term dynamic has shifted from clinical risk to manufacturing execution, with current FDA feedback focused on validating a novel, differentiated delivery system. In our view, this represents a manageable and addressable step in the approval process, rather than a structural setback. The underlying investment thesis remains intact:
• Large, established ADHD market with clear unmet needs
• Differentiated once-daily profile (rapid onset + full-day coverage)
• 505(b)(2) pathway reduces clinical risk
• Commercial infrastructure continuing to build ahead of launch
We continue to view the setup as a delay-driven dislocation rather than a fundamental impairment, with re-rating potential as regulatory clarity improves.
Valuation: We use a Discounted Cash Flow Model when valuing CING. Our model returns a range of $24.78 to $41.05 with a mid-point of $31.51.
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
SOURCE: Stonegate, Inc.
